The performance of plasma pTau181 and pTau217 in distinguishing Alzheimer's disease from various neurodegenerative disorders, psychiatric disorders, and cognitively unimpaired controls - PubMed
4 hours ago
- #Alzheimer's disease
- #Neurodegenerative disorders
- #Biomarkers
- Plasma pTau181 and pTau217 are promising biomarkers for Alzheimer's disease (AD).
- pTau181 differentiates AD from psychiatric patients (AUC: 0.879) and other participants (AUC: 0.685).
- pTau217 shows superior performance, distinguishing AD from psychiatric patients (AUC: 0.998) and other groups (AUC: 0.835).
- pTau217 is higher in AD compared to non-neurodegenerative, FTD, and synucleinopathy patients but not iNPH without age adjustment.
- The study recommends pTau217 over pTau181 for differentiating AD from non-neurodegenerative disorders.
- Further research is needed to understand pTau217's role in idiopathic normal-pressure hydrocephalus (iNPH).